Glenmark Pharmaceuticals Ltd. (GLENMARK) Share Price Falls 3.09% Amid Market Volatility
- August 3, 2026
- Posted by: Ankit Jaiswal
- Category: News
Glenmark Pharmaceuticals Ltd. Share Price fell 3.09% to Rs 2,164.4, with a market cap of Rs 63,023.91 crore.
Glenmark Pharmaceuticals Ltd. Share Price experienced a notable decline today, falling by 3.09% to close at Rs 2,164.4. This decline positions the company within the Large Cap category, with a market capitalisation of Rs 63,023.91 crore.
The decline in Glenmark Pharmaceuticals Ltd.’s share price today is a point of interest for investors and analysts alike. While the data confirms the price event, it does not establish a company-specific catalyst for the decline. This movement may prompt investors to closely monitor the company’s performance and market conditions in the coming days.
Glenmark Pharmaceuticals Ltd. (GLENMARK) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,164.4 |
| Previous Close | Rs 2,233.3 |
| Today’s Change | Rs -68.9 (-3.09%) |
| Day Open | Rs 2,269.35 |
| Day High | Rs 2,269.35 |
| Day Low | Rs 2,163 |
| Current Volume (BSE) | 19,591 |
| BSE Traded Volume | 19,591 |
| NSE Traded Volume | 4,18,137 |
| Combined NSE + BSE Volume | 4,37,728 |
| Turnover | Rs 4.24 crore |
| Market Capitalisation | Rs 63,023.91 crore |
| Market Cap Category | Large Cap |
Glenmark Pharmaceuticals Ltd. (GLENMARK) traded at Rs 2,164.4. versus the previous close of Rs 2,233.3, a fall of 3.09%. The stock opened at Rs 2,269.35, reached Rs 2,269.35, touched Rs 2,163. Reported volume was 19,591.
Glenmark Pharmaceuticals Ltd. (GLENMARK) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 63,023.91 crore |
The healthcare sector, as a whole, presents a diverse range of valuation benchmarks. The sector’s P/E median is 25.42, with an average of 88.03, indicating a wide range of valuations among companies. Similarly, the P/B median is 1.92, with an average of 2.78. These benchmarks provide a context for evaluating Glenmark Pharmaceuticals Ltd.’s financial metrics.
While the company’s specific financial ratios are not detailed in the data, understanding the broader sector context is crucial for investors. The healthcare sector’s ROE median is 10.71, and the ROCE median is 13.15, offering a benchmark for assessing profitability and efficiency. Investors may find it beneficial to compare Glenmark Pharmaceuticals Ltd.’s performance against these sector averages.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Benchmark Median P/E | 25.42x |
| Benchmark Average P/E | 88.03x |
| Benchmark P/E Range | 3.44x to 3,417.8x |
| Benchmark Median P/B | 1.92x |
| Benchmark Median ROE | 10.71% |
| Benchmark Median ROCE | 13.15% |
| Company Market Capitalisation | Rs 63,023.91 crore |
| Benchmark Median Market Cap | Rs 130.49 crore |
Glenmark Pharmaceuticals Ltd. (GLENMARK) is classified under sector: Healthcare.
Track today’s top decliners through the Univest top decliners screener. The peer table below provides the company-level comparison.
Glenmark Pharmaceuticals Ltd. is part of the healthcare sector, which encompasses a wide range of companies with varying market capitalisations and financial metrics. The sector’s benchmark includes 202 companies, providing a comprehensive overview of industry trends and performance.
Within this sector, the P/E ratio median is 25.42, with an average of 88.03, highlighting the diversity in valuations. The P/B ratio median is 1.92, with an average of 2.78, offering further insights into the sector’s financial landscape. The sector’s ROE median is 10.71, and the ROCE median is 13.15, serving as benchmarks for evaluating company performance.
Glenmark Pharmaceuticals Ltd.’s market capitalisation of Rs 63,023.91 crore positions it as a significant player within the sector. The company’s performance and valuation metrics can be assessed in relation to these sector benchmarks, providing a clearer understanding of its standing within the industry.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,931.84 | 30.09 | 0.44 | -2.89 | -0.26 |
| Hikal Ltd. | HIKAL | 2,731.11 | 0 | 2.28 | 15.22 | 16.15 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,683.28 | 39.84 | 8.11 | 28.21 | 26.35 |
| Panacea Biotec Ltd. | PANACEABIO | 2,580.49 | 0 | 3.09 | 0 | 5.36 |
| Beta Drugs Ltd. | BETA | 2,474.26 | 59.65 | 7.97 | 18.65 | 22.17 |
Glenmark Pharmaceuticals Ltd. (GLENMARK) has a market capitalisation of Rs 63,023.91 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
In the healthcare sector, Glenmark Pharmaceuticals Ltd. competes with several peers, including Dishman Carbogen Amcis Ltd., Hikal Ltd., and Kwality Pharmaceuticals Ltd. These companies vary in market capitalisation, P/E, P/B, ROE, and ROCE metrics, offering a diverse landscape for comparison.
Dishman Carbogen Amcis Ltd. has a P/E of 30.09 and a market cap of Rs 2,931.84 crore, while Hikal Ltd. has a P/B of 2.28 and a market cap of Rs 2,731.11 crore. Kwality Pharmaceuticals Ltd. stands out with a P/E of 39.84 and a ROE of 28.21, indicating strong profitability.
Comparing Glenmark Pharmaceuticals Ltd. to these peers provides valuable insights into its relative strengths and weaknesses. Investors can use this information to assess the company’s competitive position within the healthcare sector.
Why Investors Are Watching Glenmark Pharmaceuticals Ltd.
Investors are closely monitoring Glenmark Pharmaceuticals Ltd. due to its recent share price decline and position within the healthcare sector. The company’s market capitalisation and sector benchmarks offer valuable insights into its performance.
- Significant 3.09% price fall today
- Large Cap category with Rs 63,023.91 crore market cap
- Healthcare sector context and benchmarks
- Peer comparison highlights competitive position
As the market evolves, investors should continue to monitor Glenmark Pharmaceuticals Ltd.’s share price movements, sector developments, and any company-specific news that may impact its performance.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. is a prominent player in the healthcare sector, focusing on the development, manufacture, and marketing of pharmaceutical products. The company operates across various segments, including branded generics, specialty, and over-the-counter products, catering to diverse therapeutic areas.
With a strong presence in both domestic and international markets, Glenmark Pharmaceuticals Ltd. has established itself as a key player in the industry. The company’s commitment to innovation and quality has enabled it to maintain a competitive edge in the rapidly evolving pharmaceutical landscape.
Track Glenmark Pharmaceuticals Ltd. Share Price on Univest
Use Glenmark Pharmaceuticals Ltd. (GLENMARK) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners lists and related market analysis.
Investors and analysts can track Glenmark Pharmaceuticals Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, and market insights on Univest. Stay informed about the latest developments and trends affecting the company’s performance.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What was Glenmark Pharmaceuticals Ltd. Share Price today?
Ans. Glenmark Pharmaceuticals Ltd. Share Price today was Rs 2,164.4, reflecting a decline of 3.09% from the previous close of Rs 2,233.3. The stock moved -3.09% during the session. The intraday range extended from Rs 2,163 to Rs 2,269.35.
How much did Glenmark Pharmaceuticals Ltd. Share Price fall today?
Ans. Glenmark Pharmaceuticals Ltd. Share Price fell by 3.09% today, closing at Rs 2,164.4, down from the previous close of Rs 2,233.3. The stock moved -3.09% during the session. The intraday range extended from Rs 2,163 to Rs 2,269.35.
How does Glenmark Pharmaceuticals Ltd. compare to its peers?
Ans. Glenmark Pharmaceuticals Ltd. competes with peers like Dishman Carbogen Amcis Ltd. and Hikal Ltd., offering a diverse landscape for comparison in terms of market cap and financial metrics. Comparable listed companies include Dishman Carbogen Amcis Ltd., Hikal Ltd., Kwality Pharmaceuticals.
What sector does Glenmark Pharmaceuticals Ltd. operate in?
Ans. Glenmark Pharmaceuticals Ltd. operates in the healthcare sector, focusing on pharmaceuticals and drugs, with a significant presence in both domestic and international markets. The stock belongs to the Healthcare sector.
What are the sector benchmarks for Glenmark Pharmaceuticals Ltd.?
Ans. The healthcare sector benchmarks include a P/E median of 25.42 and a P/B median of 1.92, providing context for evaluating Glenmark Pharmaceuticals Ltd.’s financial metrics. The stock belongs to the Healthcare sector.
Where can I track Glenmark Pharmaceuticals Ltd. Share Price?
Ans. You can track Glenmark Pharmaceuticals Ltd. Share Price, technical indicators, and market insights on Univest for the latest updates and analysis. The stock moved -3.09% during the session. The intraday range extended from Rs 2,163 to Rs 2,269.35.
